Atomoxetine for ADHD with Comorbid Anxiety and Disruptive Mood Dysregulation Disorder

Introduction to Atomoxetine

The American Academy of Pediatrics recommends atomoxetine as a non-stimulant alternative for ADHD treatment, particularly in patients with comorbid anxiety, with an effect size of approximately 0.7 compared to placebo 4.

Atomoxetine has demonstrated efficacy in reducing both ADHD symptoms and comorbid anxiety symptoms, with the greatest anxiety improvement occurring in patients with both ADHD and anxiety disorder 1.
The medication requires 6-12 weeks to reach full therapeutic effect, which differs significantly from stimulants that work immediately 2, 1.
Atomoxetine is considered to have a safer side effect profile compared to stimulants, with lower effects on appetite and fewer growth/height problems 2, 1.

The starting dose of atomoxetine is typically 40 mg daily, with titration every 7-14 days to 60 mg, then 80 mg daily 3.
The maximum recommended dose is the lesser of 1.4 mg/kg/day or 100 mg/day 3.
The daily dose can be split into two equal doses (morning and evening) to reduce adverse effects, or if needed, can be administered in the evening only 2, 1.

It is essential to monitor for increased suicidal thoughts, particularly during initial weeks, as well as rare risks of hepatitis and cardiovascular effects 4.
The combination of atomoxetine with SSRIs like escitalopram has been studied and found to be well-tolerated, but requires monitoring of blood pressure and heart rate 4, 1.

Patient and family counseling should emphasize the importance of consistent daily dosing and the delayed onset of action, setting realistic expectations about the 6-12 week timeline to full effect 2, 1.
Regular monitoring of ADHD symptoms, anxiety symptoms, and mood is crucial, as well as watching for emergence of suicidal ideation 4.